Hypertension

New Study: Mild Hypertension Medication May Not Be Needed

16 Sep: New Study: Mild Hypertension Medication May Not Be Needed

  A whopping 40% of adults (that’s 67 million people!) throughout the world suffer from hypertension, more commonly known as high blood pressure. Over half of those people only have mild hypertension. However, in a recent study published in the British Medical Journal, a research team has indicated that the treatment of mild hypertension in patients at low risk of developing heart disease or stroke may be unnecessary. Their argument is not to leave hypertension untreated, but to determine at which level of high blood pressure treatment should begin for low-risk patients. A Little Background It has been widely accepted in the medical community for some time now that treating people for mild hypertension will reduce the risk of them…

30 Mar: FDA Shoots Down New Combo Heart Drug

Today in London the FDA decided to postpone approval of a new experimental heart drug, seeking more information about the new product. The drug called Certriad, combines AstraZeneca’s blockbuster cholesterol pill Crestor with Abbott Laboratories TriLipix. According to Rueters, The manufacturers said on Tuesday they had received a so-called “complete response letter” from the U.S. Food and Drug Administration for Certriad, which combines Astra’s blockbuster cholesterol pill Crestor and Abbott’s TriLipix. Both companies said they were evaluating the letter from the agency and would respond to the request for additional information. An AstraZeneca spokesman declined to give further details. Combo pills are fairly common for heart drugs, and most thought that FDA approval was a given. Merck merged Zocor and…

22 Feb: Neglected high blood pressure a leading cause of death in the U.S.

According to a report recently released by the Institute of Medicine, hypertension (high blood pressure) has become the second leading cause of death for people in the US. Although hypertension is easily preventable through diet, exercise and drugs, it claims one in six lives in the United States, costing our health care system upwards of 73 billion dollars this last year. The committee chair David Fleming, who directs Public Health for Seattle and King County in Washington said Hypertension as a disease is relatively easy to diagnose and it’s inexpensive to treat. Hypertension is really a neglected disease in this country. There’s a huge gap between what we could do and what we are doing. Simply reducing salt and implementing…

19 Oct: Hypertention Drug Valturna combines Diovan & Tekturna in a single pill

A new blood-pressure treatment has come on the market that is of potential interest to hypertension patients whose blood pressure is not being adequately controlled with monotherapy. Last month, the US Food and Drug Administration (FDA) approved Novartis’ Valturna (aliskiren and valsartan), which combines in a single pill valsartan, the active ingredient in Diovan, the top-selling branded high blood pressure medicine and aliskiren, the active ingredient in Tekturna — the only approved direct renin inhibitor (DRI). Valturna is the first and only medicine to target two key points within the renin system, an important regulator of blood pressure. It is suitable for patients whose high blood pressure has not been adequately controlled on aliskiren alone, or by an angiotensin receptor blocker, such as…